Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial

European urology oncology - Tập 3 - Trang 687-694 - 2020
Nizar M. Tannir1, Pavlos Msaouel1, Jeremy A. Ross1, Catherine E. Devine2, Anuradha Chandramohan2, Graciela M. Nogueras Gonzalez3, Xuemei Wang3, Jennifer Wang1, Paul G. Corn1, Zita D. Lim1, Lisa Pruitt1, Jose A. Karam4, Christopher G. Wood4, Amado J. Zurita1
1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
4Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Thông tin
Thông tin xuất bản

European urology oncology

Tập 3

687-694

Thông tin tác giả